Literature DB >> 35362853

Surgical treatment of 61 consecutive patients with maxillary stage 3 medication-related osteonecrosis of the jaws using a pedicled buccal fat pad.

Sanne Werner Moeller Andersen1, Ditte Gertz Mogensen2, Morten Schioedt2,3, Thomas Kofod2.   

Abstract

PURPOSE: Buccal fat pad (BFP) is used for the closure of large oroantral defects caused by surgical removal of the necrotic bone in patients with medication-related osteonecrosis of the jaw (MRONJ). This study aimed to evaluate the use of BFP for the closure of maxillary sinus defects in stage 3 MRONJ patients.
METHODS: This study recruited 61patients with large oroantral defects caused by MRONJ, including 49 patients with cancer and 12 patients with osteoporosis. Lesions were evaluated clinically and radiographically.
RESULTS: Among the 61 patients, 51 (83.6%) healed uneventfully, and 5 patients (8.2%) had local dehiscence and exposed bone; these 56 patients (91.8%) all healed after first or second operation. The Eastern Cooperative Oncology Group Performance Status was associated with being non-cured and might be an indicator for the healing process. All patients experienced a significant increase in body weight postoperatively.
CONCLUSIONS: This study suggest that block resection with removal of the necrotic bone combined with radical sinusotomy and closure of the defect with BFP is a reliable method to cure MRONJ lesions with a high success rate, and successful operation and prosthetic rehabilitation may improve body weight and the quality of life. The study was approved by the appropriate ethical approval for the Copenhagen ONJ Cohort (protocol no. H-6-2013-010) November 20, 2013.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Antiresorptive treatment; Buccal fat pad; Jaw osteonecrosis; MRONJ; Quality of life; Reconstruction

Year:  2022        PMID: 35362853     DOI: 10.1007/s10006-022-01061-2

Source DB:  PubMed          Journal:  Oral Maxillofac Surg        ISSN: 1865-1550


  35 in total

1.  Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer.

Authors:  Salvatore Ruggiero; Julie Gralow; Robert E Marx; Ana O Hoff; Mark M Schubert; Joseph M Huryn; Bela Toth; Kathryn Damato; Vicente Valero
Journal:  J Oncol Pract       Date:  2006-01       Impact factor: 3.840

2.  The use of buccal fat pad flap in the treatment of osteoradionecrosis.

Authors:  S Nabil; R Ramli
Journal:  Int J Oral Maxillofac Surg       Date:  2012-05-05       Impact factor: 2.789

3.  Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system.

Authors:  Morten Schiodt; Jesper Reibel; Peter Oturai; Thomas Kofod
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2013-11-15

4.  The anatomy and clinical applications of the buccal fat pad.

Authors:  J M Stuzin; L Wagstrom; H K Kawamoto; T J Baker; S A Wolfe
Journal:  Plast Reconstr Surg       Date:  1990-01       Impact factor: 4.730

5.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; Leon A Assael; Regina Landesberg; Robert E Marx; Bhoomi Mehrotra
Journal:  Aust Endod J       Date:  2009-12       Impact factor: 1.659

Review 6.  Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.

Authors:  Sven Otto; Christoph Pautke; Tim Van den Wyngaert; Daniela Niepel; Morten Schiødt
Journal:  Cancer Treat Rev       Date:  2018-06-18       Impact factor: 12.111

7.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

Authors:  Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2003-09       Impact factor: 1.895

8.  Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.

Authors:  Salvatore L Ruggiero; Bhoomi Mehrotra; Tracey J Rosenberg; Stephen L Engroff
Journal:  J Oral Maxillofac Surg       Date:  2004-05       Impact factor: 1.895

9.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

Authors:  F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carrière; R Dansey
Journal:  Ann Oncol       Date:  2011-10-10       Impact factor: 32.976

10.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.